Published in Leukemia on November 12, 2010
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics (2012) 1.63
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res (2014) 1.51
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet (2012) 1.36
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia. PLoS One (2013) 1.01
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood (2011) 1.01
Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics (2011) 0.96
Amino acid auxotrophy as a system of immunological control nodes. Nat Immunol (2015) 0.92
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet (2013) 0.84
Genetically InFormed therapies--a "GIFT" for children with cancer. Clin Cancer Res (2012) 0.83
An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet (2011) 0.83
Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst (2014) 0.82
Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet (2012) 0.81
Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs). Front Genet (2015) 0.77
Genetic Variants Contributing to Colistin Cytotoxicity: Identification of TGIF1 and HOXD10 Using a Population Genomics Approach. Int J Mol Sci (2017) 0.75
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J (2016) 0.75
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet (2008) 5.08
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet (2007) 3.05
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51
Beta-thalassemia. Genet Med (2010) 2.24
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov (2007) 2.09
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol (1997) 2.05
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2006) 1.74
Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells. Leukemia (2004) 1.66
Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J (2001) 1.49
Asparagine synthetase activity of mouse leukemias. Science (1968) 1.49
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res (1989) 1.37
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood (2002) 1.36
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood (1997) 1.28
Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat (2009) 1.26
In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood (1990) 1.26
Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet (1991) 1.26
The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood (2005) 1.25
A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res (2005) 1.24
l-asparaginase resistance in human leukemia--asparagine synthetase. Biochem Pharmacol (1969) 1.23
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer (2008) 1.23
Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett (1988) 1.21
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med (1971) 1.21
Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res (1973) 1.20
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood (1997) 1.18
Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia (1998) 1.16
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia (2008) 1.12
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood (2005) 1.11
Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin Pharmacol Ther (2007) 1.11
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 1.10
Enzymes of purine metabolism in cancer. Clin Biochem (1983) 1.06
Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol (2007) 1.03
Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet (2007) 1.01
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol (1999) 0.96
Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia (1989) 0.91
Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. Br J Cancer (1994) 0.89
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer (2006) 0.86
Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther (1998) 0.86
Argininosuccinate synthetase gene expression in leukemias: potential diagnostic marker for blastic crisis of chronic myelocytic leukemia. Leuk Res (1992) 0.86
Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One (2008) 0.80
Nucleoside incorporation into DNA and RNA in acute leukaemia: differences between the various leukaemia sub-types. Br J Haematol (1982) 0.77
Adenylosuccinate lyase as an indicator of breast and prostate malignancies: a preliminary report. Clin Biochem (1987) 0.76
CHARMM: the biomolecular simulation program. J Comput Chem (2009) 27.71
Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis (2001) 12.85
Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) (2008) 9.45
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Crystal structure of a Y-family DNA polymerase in action: a mechanism for error-prone and lesion-bypass replication. Cell (2001) 5.93
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A (2000) 5.49
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Comparison of human genetic and sequence-based physical maps. Nature (2001) 4.97
Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature (2000) 4.63
A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiol Genomics (2001) 4.50
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A (1998) 3.88
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Sequential Monte Carlo without likelihoods. Proc Natl Acad Sci U S A (2007) 3.42
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Hardness, softness, and the fukui function in the electronic theory of metals and catalysis. Proc Natl Acad Sci U S A (1985) 3.12
Classifying spatial patterns of brain activity with machine learning methods: application to lie detection. Neuroimage (2005) 2.92
Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell (1999) 2.91
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta (1998) 2.83
Short-window spectral analysis of cortical event-related potentials by adaptive multivariate autoregressive modeling: data preprocessing, model validation, and variability assessment. Biol Cybern (2000) 2.81
Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol (2001) 2.80
The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines. J Am Chem Soc (1986) 2.64
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer (2007) 2.62
Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene (2006) 2.60
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Composite active site of an ABC ATPase: MutS uses ATP to verify mismatch recognition and authorize DNA repair. Mol Cell (2001) 2.46
Crystal structure and ATPase activity of MutL: implications for DNA repair and mutagenesis. Cell (1998) 2.46
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Modulation of tRNA(iMet), eIF-2, and eIF-2B expression shows that GCN4 translation is inversely coupled to the level of eIF-2.GTP.Met-tRNA(iMet) ternary complexes. Mol Cell Biol (1995) 2.37
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res (2000) 2.32
Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst (2001) 2.27
Mutations of acidic residues in RAG1 define the active site of the V(D)J recombinase. Genes Dev (1999) 2.24
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A (1997) 2.04
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
The Polycomb group in Caenorhabditis elegans and maternal control of germline development. Development (1998) 1.97
Crystal structure of the Xrcc4 DNA repair protein and implications for end joining. EMBO J (2000) 1.94
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res (1983) 1.91
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2. Mol Cell Biol (1997) 1.89
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Structural basis for MutH activation in E.coli mismatch repair and relationship of MutH to restriction endonucleases. EMBO J (1998) 1.84
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82
Linearly polarized emission from colloidal semiconductor quantum rods. Science (2001) 1.82
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res (1998) 1.78
Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J (2005) 1.74
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Use of an Amplatz Goose Neck snare as a target for collateral neck vein dialysis catheter placement. J Vasc Interv Radiol (2001) 1.72
UV activates growth factor receptors via reactive oxygen intermediates. J Cell Biol (1996) 1.70
Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia (2010) 1.68
Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol (1996) 1.68
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer (1997) 1.66
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ (2007) 1.64
Density-functional theory of the electronic structure of molecules. Annu Rev Phys Chem (1995) 1.64
Computer use and applications in veterinary medicine. J Am Vet Med Assoc (1992) 1.64
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62